安罗替尼联合同步放化疗治疗局部晚期食管鳞状细胞癌的效果观察
Observation on the Effect of Anlotinib Combined with Concomitant Radiochemotherapy in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
王丽菲 1张洪菊 1郑英慧 1谢华2
作者信息
- 1. 聊城市传染病医院肿瘤科 山东 聊城 252000
- 2. 聊城市东昌府人民医院耳鼻喉科 山东 聊城 252000
- 折叠
摘要
目的:探讨安罗替尼与同步放化疗(CCRT)治疗局部晚期食管鳞状细胞癌的临床效果.方法:回顾性分析 2021 年 6 月 1 日—2022 年 6 月 1 日于聊城市传染病医院接受治疗的 80 例局部晚期食管鳞状细胞癌患者的临床资料,根据治疗方案分为对照组(n=38)和观察组(n=42).对照组接受CCRT治疗,观察组接受CCRT和安罗替尼联合治疗.评估两组无进展生存期(PFS)、总生存期(OS)、疾病控制率(DCR)、客观缓解率(ORR)和不良事件(AE).结果:观察组ORR、DCR分别为 69.05%、90.48%,明显高于对照组的 47.39%、63.16%,差异均有统计学意义(P<0.05).对照组中位OS为 16 个月[95%CI(14.484,17.516)],观察组为 20 个月[95%CI(15.585,24.415)],两组差异有统计学意义(x2=7.341,P=0.007),对照组中位PFS为15个月[(95%CI(9.523,20.477)],观察组为20个月[95%CI(15.581,24.419)],两组差异有统计学意义(x2=12.844,P<0.001).两组白细胞减少症、血小板减少症、贫血、胃肠道反应、放射性食管炎、皮肤反应发生率比较,差异均无统计学意义(P>0.05);观察组Ⅰ、Ⅱ级高血压发生率明显高于对照组(P<0.05).结论:安罗替尼联合CCRT治疗局部晚期食管鳞状细胞癌可提高临床疗效,延长患者生存时间.
Abstract
Objective:To explore the clinical effect of Anlotinib combined with concomitant radiochemotherapy(CCRT)in the treatment of locally advanced esophageal squamous cell carcinoma.Method:Clinical data of 80 patients with locally advanced esophageal squamous cell carcinoma treated in Liaocheng Infectious Disease Hospital from June 1,2021 to June 1,2022 were retrospectively analyzed,and divided into control group(n=38)and observation group(n=42)according to treatment regimen.The control group was treated with CCRT,and the observation group was treated with CCRT combined with Anlotinib.Progression free survival(PFS),overall survival(OS),disease control rate(DCR),objective response rate(ORR)and adverse events(AE)of the two groups were evaluated.Result:The ORR and DCR of observation group were 69.05%and 90.48%,respectively,which were significantly higher than 47.39%and 63.16%of control group,the differences were statistically significant(P<0.05).The median OS was 16 months[95%CI(14.484,17.516)]in the control group and 20 months[95%CI(15.585,24.415)]in the observation group,the difference between the two groups was statistically significant(x2=7.341,P=0.007).The median PFS was 15 months[95%CI(9.523,20.477)]in the control group and 20 months[95%CI(15.581,24.419)]in the observation group,the difference between the two groups was statistically significant(x2=12.844,P<0.001).There were no significant differences in the incidence of leucocytopenia,thrombocytopenia,anemia,gastrointestinal reaction,radiation esophagitis and cutaneous reaction between the two groups(P>0.05).The incidence of Ⅰ and Ⅱ grade hypertensive in observation group was significantly higher than that in control group(P<0.05).Conclusion:Anlotinib combined with CCRT in the treatment of locally advanced esophageal squamous cell carcinoma can improve the clinical efficacy,and prolong the survival time of patients.
关键词
安罗替尼/同步放化疗/食管鳞状细胞癌/无进展生存期/总生存期Key words
Anlotinib/Concomitant radiochemotherapy/Esophageal squamous cell carcinoma/Progression free survival/Overall survival引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据